FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

JoAnn Pinkerton

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Physiology

Anatomy

Co-author Network

Publications

TOP 3
JoAnn V Pinkerton; Kelly A Ryan; John R Thompson; Arkadi A Chines; Jennifer A Harvey; Kaijie Pan; Sebastian Mirkin
Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.
JoAnn V Pinkerton; Dearing W Johns; Lisa M Pastore; Amy L Tucker
Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome.
Jennifer A Harvey; Edmund C Baracat; Arkadi A Chines; JoAnn V Pinkerton; Harry Shi; Sebastian Mirkin
Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of JoAnn Pinkerton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: JoAnn V Pinkerton; Kelly A Ryan; John R Thompson; Arkadi A Chines; Jennifer A Harvey; Kaijie Pan; Sebastian Mirkin
Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.
Obstetrics and gynecology 2013;121(5):959-68.
2013: JoAnn V Pinkerton; Dearing W Johns; Lisa M Pastore; Amy L Tucker
Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome.
Menopause (New York, N.Y.) 2013;20(3):244-7.
2013: Jennifer A Harvey; Edmund C Baracat; Arkadi A Chines; JoAnn V Pinkerton; Harry Shi; Sebastian Mirkin
Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.
Menopause (New York, N.Y.) 2013;20(2):138-45.
2013: David F Archer; Ru-Fong J Cheng; Christine J Guico-Pabia; Eunhee Hwang; JoAnn V Pinkerton
Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
Menopause (New York, N.Y.) 2013;20(1):47-56.
2013: JoAnn V Pinkerton; David F Archer; Christine J Guico-Pabia; Eunhee Hwang; Ru-Fong J Cheng
Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Menopause (New York, N.Y.) 2013;20(1):38-46.
2013: JoAnn V Pinkerton; Ru-Fong J Cheng; Ginger D Constantine; Eunhee Hwang
Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Menopause (New York, N.Y.) 2013;20(1):28-37.
2012: JoAnn V Pinkerton; J Racketa; J H Pickar; S Mirkin
Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Climacteric : the journal of the International Menopause Society 2012;15(5):411-8.
2011: JoAnn V Pinkerton; Richard J Santen
Vaginal atrophy.
The Journal of clinical endocrinology and metabolism 2011;96(11):A27, A28.
2011: Dale W Stovall; Kirby Tanner-Kurtz; JoAnn V Pinkerton
Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
Drugs 2011;71(13):1649-57.
2011: JoAnn V Pinkerton
Pharmacological therapy for abnormal uterine bleeding.
Menopause (New York, N.Y.) 2011;18(4):453-61.
2010: JoAnn V Pinkerton; Dale W Stovall
Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Expert opinion on investigational drugs 2010;19(12):1613-21.
2010: JoAnn V Pinkerton; Dale W Stovall
Reproductive aging, menopause, and health outcomes.
Annals of the New York Academy of Sciences 2010;1204():169-78.
2010: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; GRaham Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Postmenopausal hormone therapy: an Endocrine Society scientific statement.
The Journal of clinical endocrinology and metabolism 2010;95(7 Suppl 1):s1-s66.
2010: Rebecca S Kightlinger; William Irvin; Kellie J Archer; Nancy W Huang; Raeleen A Wilson; Jacqueline R Doran; Neil B Quigley; JoAnn V Pinkerton
Cervical cancer and human papillomavirus in indigenous Guyanese women.
American journal of obstetrics and gynecology 2010;202(6):626.e1-7.
2010: JoAnn V Pinkerton; Steven R Goldstein
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Menopause (New York, N.Y.) 2010;17(3):642-53.
2010: JoAnn V Pinkerton; Christine J Guico-Pabia; Hugh S Taylor
Menstrual cycle-related exacerbation of disease.
American journal of obstetrics and gynecology 2010;202(3):221-31.
2010: JoAnn V Pinkerton; Alan C Dalkin; Sheila E Crowe; Barbara B Wilson; Edward B Stelow
Treatment of postmenopausal osteoporosis in a patient with celiac disease.
Nature reviews. Endocrinology 2010;6(3):167-71.
2009: JoAnn V Pinkerton; Wulf H Utian; Ginger D Constantine; Sophie Olivier; James H Pickar
Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Menopause (New York, N.Y.) 2009;16(6):1116-24.
2009: JoAnn V Pinkerton; David F Archer; Wulf H Utian; José C Menegoci; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Menopause (New York, N.Y.) 2009;16(6):1102-8.
2009: David F Archer; JoAnn V Pinkerton; Wulf H Utian; José C Menegoci; Tobie J de Villiers; Chui Kin Yuen; Amy B Levine; Arkadi A Chines; Ginger D Constantine
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Menopause (New York, N.Y.) 2009;16(6):1109-15.
2009: Rogerio A Lobo; JoAnn V Pinkerton; Margery L S Gass; Maxine H Dorin; Sheila Ronkin; James H Pickar; Ginger Constantine
Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Fertility and sterility 2009;92(3):1025-38.
2009: JoAnn V Pinkerton; Dale W Stovall; Rebecca S Kightlinger
Advances in the treatment of menopausal symptoms.
Women's health (London, England) 2009;5(4):361-384; quiz 383-4.
2009: JoAnn V Pinkerton; Robert A Wild
The need for evidence-based medicine to be integrated into clinical practice: role of the North American Menopause Society.
Menopause (New York, N.Y.) 2009;16(3):438-41.
2009: Dale W Stovall; JoAnn V Pinkerton
MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Current opinion in investigational drugs (London, England : 2000) 2009;10(4):365-71.
2009: JoAnn V Pinkerton; Dale W Stovall
Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk?
Menopause (New York, N.Y.) 2009;16(2):219-23.
2008: JoAnn V Pinkerton
An expert offers advice on the use of unregulated, custom-compounded hormones.
Geriatrics 2008;63(9):1 p following 20.
2008: JoAnn V Pinkerton; Patricia Dougherty; Susan C Modesitt
The effects of abuse on health problems in menopausal women.
Menopause (New York, N.Y.) 2008;15(1):1-4.
2007: JoAnn V Pinkerton; Alan C Dalkin
Combination therapy for treatment of osteoporosis: A review.
American journal of obstetrics and gynecology 2007;197(6):559-65.
2007: Lisa M Pastore; JoAnn V Pinkerton; Christopher D Williams
Triple repeat diseases and unstable gonadal function.
Fertility and sterility 2007;88(5):1477; author reply 1477.
2007: JoAnn V Pinkerton
Does addition of gabapentin to antidepressant therapy improve control of hot flashes?
Nature clinical practice. Endocrinology & metabolism 2007;3(8):566-7.
2007: JoAnn V Pinkerton; Lisa M Pastore
Perspective on menopausal vasomotor symptoms, CAM, and the SWAN.
Menopause (New York, N.Y.) 2007;14(4):601-5.
2006: JoAnn V Pinkerton
Why does NAMS need a code of ethics?
Menopause (New York, N.Y.) 2006;13(5):716-8.
2006: JoAnn V Pinkerton; Adrienne S Zion
Vasomotor symptoms in menopause: where we've been and where we're going.
Journal of women's health (2002) 2006;15(2):135-45.
2006: Lisa M Pastore; Logan B Karns; JoAnn V Pinkerton; Lawrence M Silverman; Christopher D Williams; Teresa R Camp
Acceptance of fragile X premutation genetic screening in women with ovarian dysfunction.
American journal of obstetrics and gynecology 2006;194(3):738-43.
2005: JoAnn V Pinkerton; Victor W. Henderson
Estrogen and cognition, with a focus on Alzheimer's disease.
Seminars in reproductive medicine 2005;23(2):172-9.
2005: JoAnn V Pinkerton
After the Women's Health Initiative--Menopausal Women and Hormone Therapy.
The virtual mentor : VM 2005;7(11):.
2003: Christopher D Williams; James J Finnerty; Yvonne G Newberry; Rebecca W West; Theodore S Thomas; JoAnn V Pinkerton
Reproduction in couples who are affected by human immunodeficiency virus: medical, ethical, and legal considerations.
American journal of obstetrics and gynecology 2003;189(2):333-41.
2003: JoAnn V Pinkerton; Jan L Shifren; June La Valleur; Amy Rosen; Mary Roesinger; Suresh Siddhanti
Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
Menopause (New York, N.Y.) 2003;10(1):45-52.
2002: James F Finnerty; Christopher W Fuerst; Logan B Karns; JoAnn V Pinkerton
End-of-life discussions for the primary care obstetrician/gynecologist.
American journal of obstetrics and gynecology 2002;187(2):296-301.
2002: James J Finnerty; Logan B Karns; Theodore S Thomas; Rebecca W West; JoAnn V Pinkerton
Gamete retrieval in terminal conditions: is it practical? What are the consequences?
Current women's health reports 2002;2(3):174-8.
2002: Richard J Santen; JoAnn V Pinkerton; Mark Conaway; Mary E Ropka; Lisa Wisniewski; Lawrence Demers; Karen O Klein
Treatment of urogenital atrophy with low-dose estradiol: preliminary results.
Menopause (New York, N.Y.) 2002;9(3):179-87.
2002: JoAnn V Pinkerton; Richard J Santen
Use of alternatives to estrogen for treatment of menopause.
Minerva endocrinologica 2002;27(1):21-41.
2001: Richard J Santen; JoAnn V Pinkerton; Christopher R McCartney; G R Petroni
Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.
The Journal of clinical endocrinology and metabolism 2001;86(1):16-23.
2000: James J Finnerty; JoAnn V Pinkerton; J Moreno; James E Ferguson
Ethical theory and principles: do they have any relevance to problems arising in everyday practice?
American journal of obstetrics and gynecology 2000;183(2):301-6; discussion 306-8.
1999: James J Finnerty; Christian A Chisholm; HS Chapple; Ivan S Login; JoAnn V Pinkerton
Cerebral arteriovenous malformation in pregnancy: presentation and neurologic, obstetric, and ethical significance.
American journal of obstetrics and gynecology 1999;181(2):296-303.
1999: JoAnn V Pinkerton; Richard J Santen
Alternatives to the use of estrogen in postmenopausal women.
Endocrine reviews 1999;20(3):308-20.
1998: M R Simon; Anita H Clayton; Gail J Clavet; JoAnn V Pinkerton
Patient satisfaction with psychiatric treatment of menopausal women in a multidisciplinary women's midlife center.
Menopause (New York, N.Y.) 1998;5(3):169-73.
1997: J A Harvey; JoAnn V Pinkerton; Cheryl R Herman
Short-term cessation of hormone replacement therapy and improvement of mammographic specificity.
Journal of the National Cancer Institute 1997;89(21):1623-5.
1997: JoAnn V Pinkerton; James J Finnerty; Paul A Lombardo; Mary V Rorty; HS Chapple; Robert J Boyle
Parental rights at the birth of a near-viable infant: conflicting perspectives.
American journal of obstetrics and gynecology 1997;177(2):283-8; discussion 288-90.
1996: JoAnn V Pinkerton; James J Finnerty
Resolving the clinical and ethical dilemma involved in fetal-maternal conflicts.
American journal of obstetrics and gynecology 1996;175(2):289-95.
1996: M V Rorty; JoAnn V Pinkerton
Elective fetal reduction: the ultimate elective surgery.
The Journal of contemporary health law and policy 1996;13(1):53-77.
1993: James J Finnerty; JoAnn V Pinkerton
Ethical considerations of managed care.
Obstetrical & gynecological survey 1993;48(10):699-706.
1993: James E Ferguson; B J Burkett; JoAnn V Pinkerton; S Thiagarajah; M M Flather; M M Martel; W Allen Hogge
Intraamniotic 15(s)-15-methyl prostaglandin F2 alpha and termination of middle and late second-trimester pregnancy for genetic indications: a contemporary approach.
American journal of obstetrics and gynecology 1993;169(2 Pt 1):332-9; discussion 339-40.
1993: S A Quyyumi; JoAnn V Pinkerton; William S Evans; Johannes D Veldhuis
Estradiol amplifies the amount of luteinizing hormone (LH) secreted in response to increasing doses of gonadotropin-releasing hormone by specifically augmenting the duration of evoked LH secretory events and hence their mass.
The Journal of clinical endocrinology and metabolism 1993;76(3):594-600.
1990: C F Gomez; A E Howard; JoAnn V Pinkerton; J F Childress
The Court and Webster: ethics, politics, and abortion--a panel discussion.
The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha 1990;53(4):26-30.